NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2013

Conditions

MelanomaSoft Tissue SarcomaParathyroid CarcinomaSmall Cell Carcinoma of the LungCarcinoid Tumors

Interventions

DRUG

Dacarbazine and bortezomib

Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2

Trial Locations (2)

23298

Massey Cancer Center/Virginia Commonwealth University, Richmond

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors

lead

Virginia Commonwealth University

OTHER